Donate

*Does Avodart (Dutasteride) Allow Men on Intermittent Androgen Therapy To Have A Longer “Off Period”?

Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or to receive a placebo. All of the men were receiving intermittent androgen deprivation therapy (IADT), which was stopped at month [...]

Alpha Blockers Linked to Prostate Cancer Relapse

A retrospective study has just been published that shows that the risk of experiencing a biochemical recurrence (PSA recurrence) after radical prostatectomy to treat prostate cancer increased significantly in men who received alpha blockers for lower urinary tract symptoms (LUTS) after surgery. When compared to men who did not receive alpha blockers, those who did [...]

Does ADT3 Work for Men with A Biochemical Prostate Cancer Recurrence?

One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]

Dutasteride (Avodart) Provides No Clinical Benefit to Men with Recurrent Castrate Resistant Prostate Cancer

At the University of New Mexico School of Medicine in Albuquerque, New Mexico (SKS) the Department of Urology just completed a study that showed that dutasteride, the generic name for a dual 5alpha-reductase inhibitor made by GlaxoSmithKline and marketed under the name Avodart™ in the US and Avolve™ in Europe, when administered to men with [...]

The Potental Use of Dutasteride in the Treatment of Hormone Refractory Prostate Cancer

Common practice is to treat men with advanced prostate cancer with androgen inhibition therapy (ADT) with or without antiandrogens (Casodex). Most of our prostate cancer will progress and develop into androgen-independent prostate cancer despite our achieving castrate testosterone levels. Dutasteride, a 5-alfa-reductase inhibitor, is commonly used in the treatment of benign prostatic hyperplasia (BPH). Additional, [...]

Go to Top